Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer

17th January 2025 Uncategorised 0

AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate, TROP2-directed Dato-Dxd, has crossed the U.S. regulatory finish line.

More: Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer
Source: fierce